Core Points - The Shanghai Composite Index closed at 3875.48 points, above the six-month moving average, with a slight increase of 0.14% [1] - The total trading volume of A-shares reached 1,143.939 billion yuan [1] - A total of 140 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] Summary of Key Stocks - **Top Stocks with High Deviation Rates**: - Yuekang Pharmaceutical (Code: 688658) increased by 12.29% with a deviation rate of 9.77% [1] - Fuyuan Pharmaceutical (Code: 601089) rose by 10.00%, deviation rate at 9.66% [1] - Meiyan Jixiang (Code: 600868) saw a 10.10% increase, with a deviation rate of 9.62% [1] - **Other Notable Stocks**: - Guangbai Co. (Code: 002187) up by 9.95%, deviation rate of 8.80% [1] - Chitianhua (Code: 600227) increased by 10.16%, deviation rate at 8.44% [1] - Haiwang Biological (Code: 000078) rose by 10.20%, with a deviation rate of 7.79% [1] Additional Stocks with Lower Deviation Rates - **Stocks Just Above the Six-Month Line**: - Jiahua Intelligent (Code: 300793) increased by 6.51%, deviation rate of 5.10% [1] - Henggong Precision (Code: 301261) rose by 5.41%, deviation rate at 4.97% [1] - Yingjixin (Code: 688209) saw a 7.50% increase, with a deviation rate of 4.89% [1]

Market Overview - The Shanghai Composite Index is at 3873.18 points, above the six-month moving average, with a slight increase of 0.08% [1] - The total trading volume of A-shares today is 805.55 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 161 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Yuekang Pharmaceutical: 14.13% deviation, closing at 28.03 yuan, with a daily increase of 16.79% and a turnover rate of 3.63% [1] - Fuyuan Pharmaceutical: 9.66% deviation, closing at 24.53 yuan, with a daily increase of 10.00% and a turnover rate of 1.99% [1] - Meiyan Jixiang: 9.62% deviation, closing at 3.16 yuan, with a daily increase of 10.10% and a turnover rate of 1.96% [1] Additional Stocks with Positive Performance - Other stocks with notable performance include: - Guangbai Co., Ltd.: 8.80% deviation, closing at 7.18 yuan, with a daily increase of 9.95% and a turnover rate of 5.60% [1] - Chitianhua: 8.44% deviation, closing at 2.71 yuan, with a daily increase of 10.16% and a turnover rate of 4.61% [1] - Haiwang Life: 7.79% deviation, closing at 2.81 yuan, with a daily increase of 10.20% and a turnover rate of 2.89% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month line include: - Jiangsu Guoxin, Jinmei Technology, and Zhongyuan Haifa, which have just recently crossed the six-month moving average [1]

Core Viewpoint - The innovative drug sector is experiencing significant activity, with multiple companies reaching their daily price limits. Group 1: Company Performance - Zhongheng Group, Fuyuan Pharmaceutical, Hainan Haiyao, and Peking University Pharmaceutical have all hit the daily limit up [1] - Xinhua Pharmaceutical, ST Xiangxue, and Xinnowei are among the stocks with notable gains [1]

证券日报网讯福元医药（601089）11月24日在互动平台回答投资者提问时表示，为保障信息披露的公平 原则，公司会在定期报告中依据相关法律法规披露股东人数以保证所有投资者平等获悉公司信息。 ...

Group 1 - The company held its second extraordinary general meeting on November 14, 2025, where it approved the cancellation of the supervisory board, increased the number of board seats, and revised the Articles of Association [2][13] - Wang Binchao was elected as the employee director of the third board of directors, with a term lasting until the end of the current board's term [2][5] - The board of directors now consists of 9 members, including 1 employee director, complying with relevant laws and regulations [2][3] Group 2 - The third board of directors' fourth meeting was held on November 14, 2025, where the adjustment of the audit committee members was approved [3][8] - The audit committee now includes Liu Shujin as the chairman, Xu Lin, and Wang Binchao [3][9] - The meeting was attended by all 9 directors, and the resolutions passed were deemed legal and effective [7][8] Group 3 - The company approved an investment of 323.2079 million yuan for the construction of a "High-Precision and Intelligent Pharmaceutical Industrialization Project" through its wholly-owned subsidiary [10] - The project is expected to be completed by April 2028 [10]

Core Points - The company FuYuan Pharmaceutical announced the election of Mr. Wang Binchao as the employee director of the third board of directors [2] Company Summary - FuYuan Pharmaceutical has made a significant governance change by electing a new employee director, which may reflect its commitment to employee representation in decision-making [2]

证券代码：601089 证券简称：福元医药 公告编号：临2025-078 北京福元医药股份有限公司 关于选举职工董事及调整审计委员会成员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、选举职工董事的情况 王斌超先生任公司职工董事后，公司董事中兼任高级管理人员以及由职工代表担 任的董事人数总计未超过公司董事总人数的二分之一，符合相关法律法规、规范性文 件及《公司章程》的规定。 二、董事会审计委员会成员调整情况 结合公司董事会成员变化情况，为进一步完善法人治理结构，结合公司实际情况， 公司于 2025 年 11 月 14 日召开第三届董事会第四次会议，审议通过《关于调整第三届 董事会审计委员会成员的议案》。会议以 9 票同意，0 票反对，0 票弃权通过该议案， 调整后的审计委员会成员为：刘书锦先生、徐麟先生、王斌超先生，刘书锦先生为主 任委员。 特此公告。 北京福元医药股份有限公司董事会 2025 年 11 月 15 日 附件：公司第三届董事会职工董事简历 王斌超先生，1979 年 3 月出生，中国国籍，无境外永久居留 ...

证券代码：601089 证券简称：福元医药 公告编号：临 2025-077 北京福元医药股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 11 月 14 日 (二)股东大会召开的地点：公司会议室（北京市通州区漷县镇漷县南三街 8 号） (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 188 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 350,744,168 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 74.9453 | 根据法律法规、规章和规范性文件对上市公司回购股份事宜的相关规定，上市公司回购专用 账户中的股份不享有股东会表决权，福元医药现有总股本 480,000,000 股，截至本次股东 会股权登记日，福元医药 ...

北京福元医药股份有限公司（以下简称"公司"）第三届董事会第四次会议于 2025 年 11 月 8 日以书面及邮件等方式发出会议通知，并于 2025 年 11 月 14 日在公司以现 场结合通讯表决的方式召开会议。会议应参加表决的董事 9 名，实际参加表决的董事 9 名（其中以通讯表决方式出席会议的董事 4 名）。会议由董事长黄河先生主持召开， 高级管理人员列席会议。会议召开符合法律法规、《公司法》及《公司章程》的规定， 会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于调整第三届董事会审计委员会成员的议案》 证券代码：601089 证券简称：福元医药 公告编号：临2025-079 北京福元医药股份有限公司 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （二）审议通过《关于子公司投资建设"高精尖药品数智产业化项目"的议案》 根据公司全资子公司福元药业有限公司（以下简称"福元药业"）经营发展需要， 会议同意福元药业投资建设"高精尖药品数智产业化项目"，项目投 ...

2025 年第二次临时股东会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 法律意见书 浙江天册律师事务所 关于 北京福元医药股份有限公司 关于北京福元医药股份有限公司 2025 年第二次临时股东会的 法律意见书 编号：TCYJS2025H1836 号 致：北京福元医药股份有限公司 浙江天册律师事务所（以下简称"本所"）接受北京福元医药股份有限公司 （以下简称"福元医药"或"公司"）的委托，指派本所律师参加公司 2025 年第 二次临时股东会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公司股东会》 （以下简称"《股东会规则》"）等法律、法规和其他有关规范性文件的要求出 具本法律意见书。 在本法律意见书中，本所律师仅对本次股东会召集、召开程序、出席人员的 资格、召集人的资格、表决程序及表决结果的合法有效性发表意见，不对会议所 审议的议案内容和该等议案中所表述的事实或数据的真实性和准确性发表意见。 本 ...